Stay updated with breaking news from Oncologic Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zeynep Eroglu, MD, explains the rationale for adding navitoclax to dabrafenib plus trametinib in the treatment of patients with BRAF V600–mutant metastatic melanoma, highlights the methodologies and results of the CTEP-P9466 trial, and describes the implications of this research for this patient population.
Moffitt Cancer Center experts aim to present the latest in gastric cancer research.
Rami Komrokji, MD, shares the potential clinical implications of data from the phase 3 COMMANDS trial of luspatercept in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with an erythropoiesis-stimulating agents.
Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.
Rami Komrokji, MD, discusses ongoing clinical trials in patients with higher- and lower-risk myelodysplastic syndromes.